Get the Stockscreener App
54.99
2.59%
1.39
Grail Inc stock is traded at $54.99, with a volume of 791.96K.
It is up +2.59% in the last 24 hours and up +4.48% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$53.60
Open:
$50.57
24h Volume:
791.96K
Relative Volume:
0.65
Market Cap:
$2.26B
Revenue:
$147.17M
Net Income/Loss:
$-408.35M
P/E Ratio:
-4.9192
EPS:
-11.1787
Net Cash Flow:
$-299.92M
1W Performance:
+5.43%
1M Performance:
+4.48%
6M Performance:
-15.05%
1Y Performance:
+110.37%
1-Day Range:
$50.57
$55.27
1-Week Range:
$45.79
$55.36
52-Week Range:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
54.99 | 2.26B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
Is GRAIL (GRAL) Turning Superpower Partnership Into a Scalable Edge in Preventative Oncology? - simplywall.st
Price-Driven Insight from (GRAL) for Rule-Based Strategy - Stock Traders Daily
GRAL SEC FilingsGrail Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRAIL (GRAL) Price Target Decreased by 10.52% to 85.07 - MSN
GRAL Investors Invited to Join Fraud Investigation - National Today
Here’s what analysts are saying about Grail Inc. (GRAL) - MSN
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
GRAL Technical Analysis & Stock Price Forecast - Intellectia AI
Grail (GRAL) rated buy by Guggenheim on Galleri potential - MSN
GRAIL, Inc. (GRAL) stock price, news, quote and history - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) interactive stock chart - Yahoo Finance Singapore
GRAIL, Inc. (GRAL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Superpower partners with GRAIL to offer multi-cancer blood test By Investing.com - Investing.com Australia
Grail partnering with Superpower to offer Galleri cancer early detection test - MSN
Superpower Announces Strategic Partnership With GRAIL For Multi-Cancer Early Detection Test - tradingview.com
Superpower partners with GRAIL to offer multi-cancer blood test - Investing.com
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection - prnewswire.com
Why Grail’s Stock Is Surging Again Today - TipRanks
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES - PR Newswire
Key Study of Grail’s Cancer Detection Test Fails in Setback for Company - vocal.media
Adobe Illustrator just got the holy grail of illustration tools - Fast Company
Grail (GRAL) Rated Buy by Guggenheim on Galleri Potential - insidermonkey.com
GRAIL (GRAL): Guggenheim Lowers Price Target to $75, Maintains B - GuruFocus
UBS (AMUB) offers 15.30% autocallable notes linked to GRAIL (GRAL) - Stock Titan
GRAIL, Inc. Opens with 5.11% Gain, Outperforming S&P 500's 1.01% Rise - Markets Mojo
GRAIL, Inc. Stock Hits Day Low of $47.55 Amid Price Pressure - Markets Mojo
Guggenheim Cuts GRAIL Price Target to $75 - National Today
GRAIL (NASDAQ:GRAL) Given New $75.00 Price Target at Guggenheim - marketbeat.com
Grail price target lowered to $75 from $130 at Guggenheim - TipRanks
JPMorgan Chase Boosts Stake in Cancer Screening Firm GRAIL - National Today
JPMorgan Chase & Co. Raises Stake in GRAIL, Inc. $GRAL - marketbeat.com
GRAIL (NASDAQ:GRAL) Stock Price Down 7.5%Time to Sell? - marketbeat.com
Why GRAIL Inc Shares Keep Sliding This Week - TipRanks
Vanguard disaggregates holdings; GRAIL now shows 0% ownership (GRAL) - stocktitan.net
Here's Why Grail Stock Soared Higher This Week - Yahoo Finance
Here's Why Grail Stock Soared Higher This Week - The Motley Fool
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went ... - caledonianrecord.com
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - chartmill.com
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures - AD HOC NEWS
Why Grail Stock Is Surging Back With Force - TipRanks
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
(GRAL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path - Investing.com Canada
One Fin Capital Exits GRAIL Position, Sells 380,000 SharesNews and Statistics - IndexBox
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path By Investing.com - Investing.com South Africa
Hims latest offering, Grail's Galleri cancer test, fails U.K. study - MSN
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWS
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month - The Motley Fool
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Grail Inc Stock (GRAL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Freidin Aaron | Chief Financial Officer |
Mar 05 '26 |
Sale |
53.01 |
655 |
34,722 |
308,967 |
| Ofman Joshua J. | President |
Mar 09 '26 |
Sale |
47.89 |
2,937 |
140,650 |
432,881 |
| Ofman Joshua J. | President |
Mar 05 '26 |
Sale |
53.01 |
690 |
36,577 |
435,818 |
| RAGUSA ROBERT P | Chief Executive Officer |
Mar 09 '26 |
Sale |
47.89 |
7,461 |
357,296 |
642,084 |
| RAGUSA ROBERT P | Chief Executive Officer |
Mar 05 '26 |
Sale |
53.01 |
980 |
51,950 |
649,545 |
0.17%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):